PLSM

3 - Pulsenmore Ltd. (0002064764) (Issuer)

4 - Pulsenmore Ltd. (0002064764) (Issuer)

6-K - Pulsenmore Ltd. (0002064764) (Filer)

Expanded commercial team to accelerate U.S. growth as demand for accessible prenatal care and federal rural health investments create new opportunitiesRAMAT GAN, Israel, Oct. 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM) ("Pulsenmore" or the "Company"), a pioneer in patient-operated home ultrasound technology, today announced the appointment of David Woods as Chief Commercial Officer (CCO), alongside the expansion of its U.S. commercial team, as the Company scales its presence in the U.S. healthcare market.David Woods brings more than 25 years of medtech leadership experience, most recently serving as CCO at Creo Medical. Previously, he held senior executive roles at PE

6-K - Pulsenmore Ltd. (0002064764) (Filer)

MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform into the UK fertility market where more than 100,000 IVF and fertility treatment cycles were performed in 2024.OMER, Israel, Sept. 17, 2026 /PRNewswire/ -- Pulsenmore (NASDAQ:PLSM) (TASE: PLSM), a healthcare technology company developing self-use ultrasound solutions for remote care, today announced that it has completed the registration of Pulsenmore FC with the MHRA, the UK regulatory authority responsible for medical devices. The registration enables the Company to market the system in the United Kingdom and Northern Ireland, and follows th

6-K - Pulsenmore Ltd. (0002064764) (Filer)

The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home This registration marks the Company's second product authorized in Europe and its first expansion beyond prenatal care into the broader women's health marketOMER, Israel, Sept. 8, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a healthcare technology company developing self-use ultrasound solutions for remote care, today announced that it has completed the CE European registration process for Pulsenmore FC, its home ultrasound system for monitoring follicular development and endometrial thickness during IVF and fertility preser

EFFECT - Pulsenmore Ltd. (0002064764) (Filer)

POS AM - Pulsenmore Ltd. (0002064764) (Filer)

S-8 - Pulsenmore Ltd. (0002064764) (Filer)

6-K - Pulsenmore Ltd. (0002064764) (Filer)

Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business UpdateOMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, presents the key operational, commercial, regulatory, and technological achievements as well as financial updates for the six month period ended June 30, 2026. During the first half of 2026, Pulsenmore advanced its commercialization efforts in the United States following FDA marketing authorization for its home ultrasound platform, while continuing to advance produ

OMER, Israel, Aug. 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, today announces that it will release its financial results and business highlights for the six months ended June 30, 2026 on August 31, 2026 at 8:30 am ET. The Company will host a webcast on the same day to discuss its financial results, business highlights, and recent progress.Webcast DetailsDate: August 31, 2026 at 8:30am Eastern Time / 3:30pm Israel Time.Webcast: https://teams.microsoft.com/meet/35050418577919?p=r5gfAIMDL65KJ8zKj3 Replay: A replay of t

6-K - Pulsenmore Ltd. (0002064764) (Filer)

The Company's home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov, expanding the ability to incorporate at-home ultrasound scans as part of pregnancy monitoringRAMAT GAN, Israel, Aug. 19, 2026 /PRNewswire/ -- Pulsenmore (NASDAQ:PLSM) (TASE: PLSM), a developer of home ultrasound solutions supported by remote medical guidance, today announced the expansion of its activities in Israel. The Company's home ultrasound technology will be integrated at the Lis Maternity and Women's Hospital at Ichilov, a major center for women's and maternity care in Israel, joining other medical centers that already incorporate the technology into pregnancy monitoring path

6-K - Pulsenmore Ltd. (0002064764) (Filer)

The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of approximately $3.12 million.The program is designed to advance the next generation of home ultrasound through AI-powered real-time ultrasound analysis and dynamic guidance of the image acquisition process, with the goal of improving scan quality and consistency and enabling home ultrasound to be deployed at greater scale.RAMAT GAN, Israel, Aug. 17, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a global leader in home ultrasound technology, today announced that the Israel Innovation Authority has approved a gran

6-K - Pulsenmore Ltd. (0002064764) (Filer)

424B3 - Pulsenmore Ltd. (0002064764) (Filer)

DENVER, July 13, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- From a transformational merger and corporate restructuring at Twin Vee PowerCats, to encouraging Phase 2 clinical data from Q32 Bio, major oncology financing by Agenus, government-backed AI development at Pulsenmore, shareholder returns from LogProstyle, and new third-party testing validating Xeriant's advanced construction materials, this week's developments demonstrate the diverse catalysts capable of reshaping small-cap growth stories. Twin Vee PowerCats (NASDAQ:VEEE) announced one of the week's most significant corporate restructurings through a definitive agreement that combines a merger with privately held USFM Corpora

6-K - Pulsenmore Ltd. (0002064764) (Filer)

The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound platform. RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a pioneer in connected home ultrasound technology, today announced that it has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (IIA) and the Ministry of Health. Pulsenmore will receive funding from the IIA as part of a project.The program is designed to accelerate the adoption of breakthrough healthcare AI technolo

EFFECT - Pulsenmore Ltd. (0002064764) (Filer)

D - Pulsenmore Ltd. (0002064764) (Filer)